Clinical Trial Update: Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating inhaled fosfomycin/tobramycin for cystic fibrosis patients with Pseudomonas aeruginosa lung infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• fosfomycin/tobramycin inhalation (fosfomycin-tobramycin inhalation solution)

Snippet

Sponsor: Gilead Sciences | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED